Stefania Cuzzubbo

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

Long-term treatment outcomes of immune checkpoint inhibitor-related neuropathies: a French multicenter cohort study.

Long-term treatment outcomes of immune checkpoint inhibitor-related neuropathies: a French multicenter cohort study.

Journal: Scientific reports

Published: February 25, 2026

Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature.

Optic neuropathies induced by immune checkpoint inhibitors: A case series and systematic review of the literature.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 19, 2025

Outlook for the management of glioblastoma

Outlook for the management of glioblastoma

Journal: La Revue du praticien

Published: October 23, 2025

Neurotoxicity from chimeric antigen receptor T-cells: an update on diagnosis and treatment.

Neurotoxicity from chimeric antigen receptor T-cells: an update on diagnosis and treatment.

Journal: Current opinion in neurology

Published: August 01, 2025

Early onset radiation-induced leukoencephalopathy in patients treated for a glioblastoma by STUPP protocol and risk factors evaluation, an ancillary study of the phase III ASTER protocol.

Early onset radiation-induced leukoencephalopathy in patients treated for a glioblastoma by STUPP protocol and risk factors evaluation, an ancillary study of the phase III ASTER protocol.

Journal: Revue neurologique

Published: May 29, 2025

Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of ICANS in CAR T-Cell Therapy for Aggressive B-Cell Lymphoma.

Baseline Cognitive and Neurological Status Does Not Modify the Occurrence of ICANS in CAR T-Cell Therapy for Aggressive B-Cell Lymphoma.

Journal: European journal of neurology

Published: January 24, 2025

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Survival Outcomes Associated With First-Line Procarbazine, CCNU, and Vincristine or Temozolomide in Combination With Radiotherapy in IDH-Mutant 1p/19q-Codeleted Grade 3 Oligodendroglioma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 02, 2024

CAR T-cell-associated neurotoxicity: A comprehensive review.

CAR T-cell-associated neurotoxicity: A comprehensive review.

Journal: Revue neurologique

Published: June 18, 2024

REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.

REVOLUMAB: A phase II trial of nivolumab in recurrent IDH mutant high-grade gliomas.

Journal: European journal of cancer (Oxford, England : 1990)

Published: March 02, 2024

Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.

Mismatch Repair Deficiency and Lynch Syndrome Among Adult Patients With Glioma.

Journal: JCO precision oncology

Published: June 01, 2023

Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy.

Synthetic Melanin Acts as Efficient Peptide Carrier in Cancer Vaccine Strategy.

Journal: International journal of molecular sciences

Published: October 21, 2022

Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment.

Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment.

Journal: Current opinion in neurology

Published: October 13, 2022

Showing 1-12 of 32

Last Updated: 09/26/2026